1. Home
  2. VLTO vs ILMN Comparison

VLTO vs ILMN Comparison

Compare VLTO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veralto Corp

VLTO

Veralto Corp

HOLD

Current Price

$100.43

Market Cap

24.5B

Sector

Industrials

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$135.14

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VLTO
ILMN
Founded
2023
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.5B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
VLTO
ILMN
Price
$100.43
$135.14
Analyst Decision
Buy
Hold
Analyst Count
9
16
Target Price
$113.25
$116.19
AVG Volume (30 Days)
2.1M
1.8M
Earning Date
02-03-2026
02-05-2026
Dividend Yield
0.52%
N/A
EPS Growth
12.64
N/A
EPS
3.65
4.46
Revenue
$5,452,000,000.00
$4,288,000,000.00
Revenue This Year
$8.28
N/A
Revenue Next Year
$5.83
$2.08
P/E Ratio
$27.56
$30.22
Revenue Growth
6.15
N/A
52 Week Low
$83.87
$68.70
52 Week High
$110.11
$153.06

Technical Indicators

Market Signals
Indicator
VLTO
ILMN
Relative Strength Index (RSI) 52.36 64.21
Support Level $98.42 $129.29
Resistance Level $101.75 $137.09
Average True Range (ATR) 1.72 3.84
MACD 0.12 -0.64
Stochastic Oscillator 53.28 82.09

Price Performance

Historical Comparison
VLTO
ILMN

About VLTO Veralto Corp

Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: